Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Oncology in Clinical Practice
MENU
Shortcuts Submit an article Author Guidelines Ahead Of Print Reviewers 2022 Professor Krzysztof Krzemieniecki Award

open access

Vol 15, No 2 (2019)
Research paper
Published online: 2019-05-17
View PDF Download PDF file
Get Citation

Consistency in biomarkers expression between matched tissue microarray cores from primary gallblader and ovarian cancers

Beata Hryciuk1, Bartosz Szymanowski2, Michał Bieńkowski3, Adrian Perdyan4, Aleksandra Korwat3, Kamil Winnik5, Barbara Radecka6, Jolanta Żok7, Natalia Cichowska8, Katarzyna Sosińska-Mielcarek8, Rafał Pęksa3, Renata Duchnowska1
DOI: 10.5603/OCP.2019.0011
·
Oncol Clin Pract 2019;15(2):85-88.
Affiliations
  1. Mazovian Centre for Lung Diseases and Tuberculosis, Division III, Otwock, Poland
  2. Oncology Clinic Military Institute of Medicine, Warsaw, Poland
  3. Chair and Department of Pathomorphology, Medical University of Gdansk, Poland
  4. Medical Faculty, Medical University of Gdansk, Poland
  5. Department of Pathomorphology, of Janusz Korczak Provincial Specialist Hospital in Slupsk, Poland
  6. Institute of Medicine, Opole University, Opole, Poland
  7. Provincial Centre of Oncology in Gdansk, Poland
  8. Department of Oncology and Radiotherapy, Medical University of Gdansk, Poland

open access

Vol 15, No 2 (2019)
ORIGINAL ARTICLE
Published online: 2019-05-17

Abstract

Introduction. Tissue microarray (TMA) technique has been widely used, especially in immunohistochemical assays of new prognostic and predictive markers. The main objections raised by its opponents are the small amount of sampled material and the associated risk of inadequate assessment of analysed expression, resulting from the potential heterogeneity of tumour tissue. Material and methods. This study evaluated the compatibility of biomarker expression in two independent tissue cores, 1.5 mm in diameter, obtained by TMA technique from patients with gallbladder cancer (ERb, cytoPgR, HER2, CTGF) and ovarian cancer (PTEN, BCL2, PIK3CA, IGF1R). Comparison of the expression of individual biomarkers between cores was performed using the intraclass correlation coefficient (ICC), assuming a kappa < 0.4 as a weak, ≥ 0.4 as sufficient, ≥ 0.6 as good, and ≥ 0.75 as optimal correlation, and Kendall’s tau test — ICC package. Results. Evaluation of biomarker expression in the primary tumour was performed in 60 patients with gallbladder cancer and in 64 patients with high-grade serous ovarian cancer. Additionally, in patients with follicular cancer, the expression of the tested markers was assessed in the epithelium free from neoplastic malignancy. In both tumours, a good or sufficient level of homogeneity was observed in the expression of the analysed biomarkers between tissue cores. The correlation coefficient for the expression of individual markers in gallbladder cancer and adhering healthy tissue was: 0.68 (95% CI: 0.53–0.79)/0.62 (95% CI: 0.39–0.78) for ERb, 0.44 (95% CI: 0.23–0.61)/0.77 (95% CI: 0.61–0.87) for cytoPgR, 0.77 (95% CI: 0.65–0.85)/0.66 (95% CI: 0.44–0.80) for HER2, and 0.68 (95% CI: 0.53–0.79)/0.62 (95% CI: 0.39–0.78) for CTGF. In patients with ovarian cancer, the correlation coefficient within the primary tumour was 0.82 (95% CI: 0.71–0.89) for PTEN, 0.84 (95% CI: 0.75–0.90) for BCL2, 0.71 (95% CI: 0.56–0.81) for PIK3CA, and 0.77 (95% CI: 0.65–0.85) for IGF1R. Conclusions. Tissue microarray technique allows reliable assessment of the expression of tissue biomarkers within the primary tumour of gallbladder cancer and ovarian cancer.

Abstract

Introduction. Tissue microarray (TMA) technique has been widely used, especially in immunohistochemical assays of new prognostic and predictive markers. The main objections raised by its opponents are the small amount of sampled material and the associated risk of inadequate assessment of analysed expression, resulting from the potential heterogeneity of tumour tissue. Material and methods. This study evaluated the compatibility of biomarker expression in two independent tissue cores, 1.5 mm in diameter, obtained by TMA technique from patients with gallbladder cancer (ERb, cytoPgR, HER2, CTGF) and ovarian cancer (PTEN, BCL2, PIK3CA, IGF1R). Comparison of the expression of individual biomarkers between cores was performed using the intraclass correlation coefficient (ICC), assuming a kappa < 0.4 as a weak, ≥ 0.4 as sufficient, ≥ 0.6 as good, and ≥ 0.75 as optimal correlation, and Kendall’s tau test — ICC package. Results. Evaluation of biomarker expression in the primary tumour was performed in 60 patients with gallbladder cancer and in 64 patients with high-grade serous ovarian cancer. Additionally, in patients with follicular cancer, the expression of the tested markers was assessed in the epithelium free from neoplastic malignancy. In both tumours, a good or sufficient level of homogeneity was observed in the expression of the analysed biomarkers between tissue cores. The correlation coefficient for the expression of individual markers in gallbladder cancer and adhering healthy tissue was: 0.68 (95% CI: 0.53–0.79)/0.62 (95% CI: 0.39–0.78) for ERb, 0.44 (95% CI: 0.23–0.61)/0.77 (95% CI: 0.61–0.87) for cytoPgR, 0.77 (95% CI: 0.65–0.85)/0.66 (95% CI: 0.44–0.80) for HER2, and 0.68 (95% CI: 0.53–0.79)/0.62 (95% CI: 0.39–0.78) for CTGF. In patients with ovarian cancer, the correlation coefficient within the primary tumour was 0.82 (95% CI: 0.71–0.89) for PTEN, 0.84 (95% CI: 0.75–0.90) for BCL2, 0.71 (95% CI: 0.56–0.81) for PIK3CA, and 0.77 (95% CI: 0.65–0.85) for IGF1R. Conclusions. Tissue microarray technique allows reliable assessment of the expression of tissue biomarkers within the primary tumour of gallbladder cancer and ovarian cancer.

Full Text:

View PDF Download PDF file
Get Citation

Keywords

tissue microarrays; biomarkers; gallbladder cancer; ovarian cancer

About this article
Title

Consistency in biomarkers expression between matched tissue microarray cores from primary gallblader and ovarian cancers

Journal

Oncology in Clinical Practice

Issue

Vol 15, No 2 (2019)

Article type

Research paper

Pages

85-88

Published online

2019-05-17

Page views

423

Article views/downloads

443

DOI

10.5603/OCP.2019.0011

Bibliographic record

Oncol Clin Pract 2019;15(2):85-88.

Keywords

tissue microarrays
biomarkers
gallbladder cancer
ovarian cancer

Authors

Beata Hryciuk
Bartosz Szymanowski
Michał Bieńkowski
Adrian Perdyan
Aleksandra Korwat
Kamil Winnik
Barbara Radecka
Jolanta Żok
Natalia Cichowska
Katarzyna Sosińska-Mielcarek
Rafał Pęksa
Renata Duchnowska

References (19)
  1. Battifora H. The multitumor (sausage) tissue block: novel method for immunohistochemical antibody testing. Lab Invest. 1986; 55(2): 244–248.
    PubMed
  2. Hewitt SM. Tissue microarrays as a tool in the discovery and validation of predictive biomarkers. Methods Mol Biol. 2012; 823: 201–214.
    CrossRefPubMed
  3. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998; 4(7): 844–847.
    PubMed
  4. Camp RL, Neumeister V, Rimm DL. A decade of tissue microarrays: progress in the discovery and validation of cancer biomarkers. J Clin Oncol. 2008; 26(34): 5630–5637.
    CrossRefPubMed
  5. Team RC (2015) R: A Language and Environment for Statistical Computing (R Foundation for Statistical Computing, Vienna, 2015). http://www.R-project.org.
  6. Wolak ME, Fairbairn DJ, Paulsen YR. Guidelines for estimating repeatability. Methods in Ecology and Evolution. 2012; 3: 129–137.
  7. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012; 366(10): 883–892.
    CrossRefPubMed
  8. Gerlinger M, Horswell S, Larkin J, et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat Genet. 2014; 46(3): 225–233.
    CrossRefPubMed
  9. Seoane J, De Mattos-Arruda L. The challenge of intratumour heterogeneity in precision medicine. J Intern Med. 2014; 276(1): 41–51.
    CrossRefPubMed
  10. Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab Invest. 2000; 80(12): 1943–1949.
    PubMed
  11. Zhang D, Salto-Tellez M, Putti TC, et al. Reliability of tissue microarrays in detecting protein expression and gene amplification in breast cancer. Mod Pathol. 2003; 16(1): 79–84.
    CrossRefPubMed
  12. Fonseca FP, de Andrade BA, Rangel AL, et al. Tissue microarray is a reliable method for immunohistochemical analysis of pleomorphic adenoma. Oral Surg Oral Med Oral Pathol Oral Radiol. 2014; 117(1): 81–88.
    CrossRefPubMed
  13. Khouja MH, Baekelandt M, Sarab A, et al. Limitations of tissue microarrays compared with whole tissue sections in survival analysis. Oncol Lett. 2010; 1(5): 827–831.
    CrossRefPubMed
  14. Griffin MC, Robinson RA, Trask DK. Validation of tissue microarrays using p53 immunohistochemical studies of squamous cell carcinoma of the larynx. Mod Pathol. 2003; 16(12): 1181–1188.
    CrossRefPubMed
  15. Jourdan F, Sebbagh N, Comperat E, et al. Tissue microarray technology: validation in colorectal carcinoma and analysis of p53, hMLH1, and hMSH2 immunohistochemical expression. Virchows Arch. 2003; 443(2): 115–121.
    CrossRefPubMed
  16. Gomaa W, Ke Y, Fujii H, et al. Tissue microarray of head and neck squamous carcinoma: validation of the methodology for the study of cutaneous fatty acid-binding protein, vascular endothelial growth factor, involucrin and Ki-67. Virchows Arch. 2005; 447(4): 701–709.
    CrossRefPubMed
  17. Su Y, Shrubsole MJ, Ness RM, et al. Immunohistochemical expressions of Ki-67, cyclin D1, beta-catenin, cyclooxygenase-2, and epidermal growth factor receptor in human colorectal adenoma: a validation study of tissue microarrays. Cancer Epidemiol Biomarkers Prev. 2006; 15(9): 1719–1726.
    CrossRefPubMed
  18. Rosen DG, Huang X, Deavers MT, et al. Validation of tissue microarray technology in ovarian carcinoma. Mod Pathol. 2004; 17(7): 790–797.
    CrossRefPubMed
  19. Leversha MA, Fielding P, Watson S, et al. Expression of p53, pRB, and p16 in lung tumours: a validation study on tissue microarrays. J Pathol. 2003; 200(5): 610–619.
    CrossRefPubMed

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl